高危KMT2A重排婴儿急性淋巴细胞白血病的造血干细胞移植
多变量分析显示巩固治疗结束时MRD阳性是唯一与较差EFS相关的因素(P<.001)。
要点
- 高危KMT2A-r婴儿ALL在强化化疗基础上行HSCT可获得3年EFS 56.8%、OS 80.2%。
- 巩固治疗结束时MRD阳性(≥0.01%)是唯一与较差EFS独立相关的因素(P<.001)。
- 鉴于严重毒性和远期效应风险,HSCT指征应进一步限制或未来取消。
核心结论
- 移植前快速清除MRD和定制HSCT策略使高危KMT2A-r婴儿ALL获得良好结局。
- 但考虑到高比例潜在危及生命的毒性和远期效应风险,其指征应进一步限制或未来取消。
研究设计与样本
- 日本儿童白血病/淋巴瘤研究组MLL-10试验,高危患者56例,49例达完全缓解。
主要发现
- 56例高危患者的3年无事件生存率为56.8%(95%CI 42.4%–68.8%),总生存率为80.2%(95%CI 67.1%–88.5%)。
- 单变量分析显示,Interfant-HR标准和诱导结束时及巩固结束时流式细胞术MRD≥0.01%均与较差EFS显著相关。
- 多变量分析中,巩固治疗结束时MRD阳性是唯一与较差EFS相关的因素(P<.001)。
关键数值与推荐
- HSCT指征限定为高危特征:KMT2A-r且年龄<180天或存在中枢神经系统白血病。
- MRD阳性定义为流式细胞术检测≥0.01%。
临床怎么用
- 对高危KMT2A-r婴儿ALL,可在强化化疗后按方案行个体化靶剂量预处理HSCT。
- 巩固治疗结束时MRD状态可用于识别HSCT后EFS较差的高危患者。
- 需权衡HSCT的严重毒性和远期效应风险,严格掌握指征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of allogeneic hematopoietic stem cell transplantation (HSCT) for infants with acute lymphoblastic leukemia (ALL) and KMT2A gene rearrangement (KMT2A-r) is controversial in terms of both its efficacy and potential for acute and late toxicities. In Japanese Pediatric Leukemia/Lymphoma Study Group trial MLL-10, by introducing intensive chemotherapy, indication of HSCT was restricted to patients with high-risk (HR) features only (KMT2A-r and either age <180 days or presence of central nervous system leukemia). Of the 56 HR patients, 49 achieved complete remission. Forty-three patients received HSCT in first remission including 38 patients receiving protocol-specified HSCT with conditioning consisting of individualized targeted doses of busulfan, etoposide, and cyclophosphamide. Three-year event-free survival (EFS) of 56.8% (95% confidence interval [CI], 42.4% to 68.8%) and overall survival of 80.2% (95% CI, 67.1% to 88.5%) were accomplished. Univariable analysis showed that Interfant-HR criteria and flow cytometric minimal residual disease (MRD; ≥0.01%), both at the end of induction and at the end of consolidation (EOC), were significantly associated with poorer EFS. In the multivariable analysis, positive MRD at EOC was solely associated with poor EFS (P < .001). Rapid pretransplant MRD clearance and tailored HSCT strategy in the MLL-10 trial resulted in a favorable outcome for infants with HR KMT2A-r ALL. However, considering the high rate of potentially life-threatening toxicities and the risk of late effects, its indication should be further restricted or even eliminated in the future by introducing more effective therapeutic modalities with minimal toxicities. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as #UMIN000004801.
引用
- Takachi T, Watanabe T, Miyamura T, et al. Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia. Blood Adv. 2021. PMID: 34500465. doi:10.1182/bloodadvances.2020004157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。